ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award

Arca Biopharma Inc (ABIO) on September 13, 2016 announced that is has been named as one of the winners of the Corporate LiveWire 2016 Healthcare and Lifesciences Awards with the award for Excellence in Developing Cardiovascular Disease Therapies. ARCA’s GENETIC-AF clinical trial is a seamless design Phase 2B/3 clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential treatment for atrial fibrillation.

“It is gratifying to see the hard work and dedication of our employees and clinical investigators recognized with this award,” said Dr. Michael R. Bristow, President and Chief Executive Officer of ARCA. “We believe we have an opportunity to potentially improve the treatment options for patients at risk for, or living with, atrial fibrillation, by addressing an unmet medical need in patients who also have heart failure and/or left ventricular dysfunction. We believe the Gencaro development program, if successful in GENETIC-AF, would also herald a new era of pharmacogenetically developed cardiovascular drugs.”

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information, please visit www.arcabio.com.